CN107921065A - 通过t细胞疗法治疗cmv视网膜炎的方法 - Google Patents
通过t细胞疗法治疗cmv视网膜炎的方法 Download PDFInfo
- Publication number
- CN107921065A CN107921065A CN201680049106.8A CN201680049106A CN107921065A CN 107921065 A CN107921065 A CN 107921065A CN 201680049106 A CN201680049106 A CN 201680049106A CN 107921065 A CN107921065 A CN 107921065A
- Authority
- CN
- China
- Prior art keywords
- allogeneic
- cells
- cmv
- cell
- specific embodiment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 491
- 238000000034 method Methods 0.000 title claims abstract description 141
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 title claims description 94
- 208000001763 cytomegalovirus retinitis Diseases 0.000 title claims description 94
- 238000002659 cell therapy Methods 0.000 title description 7
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 292
- 241000701022 Cytomegalovirus Species 0.000 claims abstract description 187
- 210000000056 organ Anatomy 0.000 claims abstract description 40
- 239000007787 solid Substances 0.000 claims abstract description 35
- 206010038910 Retinitis Diseases 0.000 claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims description 98
- 108700028369 Alleles Proteins 0.000 claims description 69
- 229960002963 ganciclovir Drugs 0.000 claims description 68
- 238000011282 treatment Methods 0.000 claims description 49
- 238000000338 in vitro Methods 0.000 claims description 38
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 claims description 37
- 238000001802 infusion Methods 0.000 claims description 37
- 229960002149 valganciclovir Drugs 0.000 claims description 37
- 239000000427 antigen Substances 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 36
- 230000003442 weekly effect Effects 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 238000002054 transplantation Methods 0.000 claims description 35
- 230000035772 mutation Effects 0.000 claims description 30
- 230000000840 anti-viral effect Effects 0.000 claims description 28
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 25
- 229960000724 cidofovir Drugs 0.000 claims description 25
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 24
- 229960000681 leflunomide Drugs 0.000 claims description 24
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 22
- 238000011068 loading method Methods 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 239000003443 antiviral agent Substances 0.000 claims description 17
- 210000004443 dendritic cell Anatomy 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 210000001616 monocyte Anatomy 0.000 claims description 17
- 206010070834 Sensitisation Diseases 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 14
- 230000008313 sensitization Effects 0.000 claims description 14
- 101150009795 UL54 gene Proteins 0.000 claims description 13
- 208000030507 AIDS Diseases 0.000 claims description 11
- 210000003734 kidney Anatomy 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 238000003205 genotyping method Methods 0.000 claims description 6
- 108091008048 CMVpp65 Proteins 0.000 claims description 5
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 5
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 5
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 5
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 5
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 5
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 101900065606 Human cytomegalovirus Immediate early protein IE1 Proteins 0.000 claims description 3
- 108091008874 T cell receptors Proteins 0.000 claims description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 208000007654 attenuated familial adenomatous polyposis Diseases 0.000 claims 8
- 238000010828 elution Methods 0.000 claims 5
- 230000002155 anti-virotic effect Effects 0.000 claims 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 230000008014 freezing Effects 0.000 claims 2
- 238000007710 freezing Methods 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000000151 deposition Methods 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 229940116254 phosphonic acid Drugs 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 92
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 65
- 229960005102 foscarnet Drugs 0.000 description 46
- 238000001990 intravenous administration Methods 0.000 description 41
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 238000002347 injection Methods 0.000 description 29
- 239000007924 injection Substances 0.000 description 29
- 230000001235 sensitizing effect Effects 0.000 description 26
- 210000001508 eye Anatomy 0.000 description 23
- 238000002560 therapeutic procedure Methods 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 210000001525 retina Anatomy 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 230000002207 retinal effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 229940100688 oral solution Drugs 0.000 description 10
- 206010061598 Immunodeficiency Diseases 0.000 description 9
- 101150060933 UL97 gene Proteins 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 206010046851 Uveitis Diseases 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 230000004438 eyesight Effects 0.000 description 7
- 210000004155 blood-retinal barrier Anatomy 0.000 description 6
- 230000004378 blood-retinal barrier Effects 0.000 description 6
- 238000010257 thawing Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 206010058854 Cytomegalovirus viraemia Diseases 0.000 description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
- 206010062016 Immunosuppression Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000004393 visual impairment Effects 0.000 description 5
- 101000979735 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100024975 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000007969 cellular immunity Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000002998 immunogenetic effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000007420 reactivation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 208000014912 Central Nervous System Infections Diseases 0.000 description 2
- 206010010430 Congenital cytomegalovirus infection Diseases 0.000 description 2
- 208000001351 Epiretinal Membrane Diseases 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 229940124060 PD-1 antagonist Drugs 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000003339 best practice Methods 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001296 transplacental effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100028559 Death domain-associated protein 6 Human genes 0.000 description 1
- 101710091772 Death domain-associated protein 6 Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- ZORWARFPXPVJLW-MTFPJWTKSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]-3-hydroxypropyl] (2s)-2-amino-3-methylbutanoate;hydron;chloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 ZORWARFPXPVJLW-MTFPJWTKSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008397 ocular pathology Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960004983 valganciclovir hydrochloride Drugs 0.000 description 1
- 230000008403 visual deficit Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185558P | 2015-06-26 | 2015-06-26 | |
| US62/185,558 | 2015-06-26 | ||
| US201562191304P | 2015-07-10 | 2015-07-10 | |
| US62/191,304 | 2015-07-10 | ||
| PCT/US2016/038530 WO2016209816A1 (en) | 2015-06-26 | 2016-06-21 | Methods of treating cmv retinitis by t cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107921065A true CN107921065A (zh) | 2018-04-17 |
Family
ID=56404300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680049106.8A Pending CN107921065A (zh) | 2015-06-26 | 2016-06-21 | 通过t细胞疗法治疗cmv视网膜炎的方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10342864B2 (https=) |
| EP (2) | EP3756676B1 (https=) |
| JP (1) | JP2018518527A (https=) |
| CN (1) | CN107921065A (https=) |
| HK (1) | HK1254397A1 (https=) |
| WO (1) | WO2016209816A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| PT2812431T (pt) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes para gerar ctls multivirais com larga especifidade |
| JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
| AU2018355145A1 (en) | 2017-10-23 | 2020-04-30 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
| US20210000874A1 (en) | 2018-03-14 | 2021-01-07 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line for adoptive cellular therapy |
| EP3978554A4 (en) * | 2019-05-28 | 2023-06-21 | Toyobo Co., Ltd. | POLYESTER FILM, LAMINATED FILM AND USE THEREOF |
| MX2022001322A (es) * | 2019-07-29 | 2022-05-24 | Baylor College Medicine | Bancos de células t específicas de antígeno y métodos para fabricar y usar los mismos terapéuticamente. |
| RU2740943C1 (ru) * | 2020-03-23 | 2021-01-21 | Борис Сергеевич Першин | Способ лечения цитомегаловирусного ретинита после трансплантации гемопоэтических стволовых клеток |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1237909A (zh) * | 1996-10-11 | 1999-12-08 | 加利福尼亚大学董事会 | 联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗 |
| CN1575181A (zh) * | 2001-01-30 | 2005-02-02 | 印斯拜尔药品股份有限公司 | 在视网膜疾病中用二核苷酸多磷酸促进液体的去除 |
| CN1617668A (zh) * | 2001-11-29 | 2005-05-18 | 特拉科斯有限公司 | 用体外光提取法和/或凋亡细胞对被试者进行预治疗的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595978A (en) * | 1990-08-16 | 1997-01-21 | Isis Pharmaceuticals, Inc. | Composition and method for treatment of CMV retinites |
| US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6156317A (en) | 1996-11-12 | 2000-12-05 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| ATE497971T1 (de) | 1999-06-04 | 2011-02-15 | Florian Kern | Peptide zur vakzinierung gegen das humane cmv |
| AU2002214624A1 (en) | 2000-10-20 | 2002-05-06 | City Of Hope | Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150 |
| US7718196B2 (en) | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
| WO2003073097A2 (en) | 2002-02-28 | 2003-09-04 | Intercell Ag | Methods for isolating ligands e.g. t cell epitopes |
| US7163685B2 (en) * | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| CA2744449C (en) | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB0917094D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| WO2013063436A1 (en) * | 2011-10-26 | 2013-05-02 | Chimerix, Inc. | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| GB201121308D0 (en) * | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| WO2017003763A1 (en) * | 2015-06-27 | 2017-01-05 | Memorial Sloan Kettering Cancer Center | Methods of treating glioblastoma multiforme by t cell therapy |
-
2016
- 2016-06-21 HK HK18113474.8A patent/HK1254397A1/zh unknown
- 2016-06-21 WO PCT/US2016/038530 patent/WO2016209816A1/en not_active Ceased
- 2016-06-21 EP EP20190952.0A patent/EP3756676B1/en active Active
- 2016-06-21 CN CN201680049106.8A patent/CN107921065A/zh active Pending
- 2016-06-21 JP JP2017567429A patent/JP2018518527A/ja active Pending
- 2016-06-21 EP EP16736962.8A patent/EP3313419B1/en active Active
- 2016-06-24 US US15/191,773 patent/US10342864B2/en active Active
-
2019
- 2019-05-23 US US16/420,876 patent/US11103577B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1237909A (zh) * | 1996-10-11 | 1999-12-08 | 加利福尼亚大学董事会 | 联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗 |
| CN1575181A (zh) * | 2001-01-30 | 2005-02-02 | 印斯拜尔药品股份有限公司 | 在视网膜疾病中用二核苷酸多磷酸促进液体的去除 |
| CN1617668A (zh) * | 2001-11-29 | 2005-05-18 | 特拉科斯有限公司 | 用体外光提取法和/或凋亡细胞对被试者进行预治疗的方法 |
Non-Patent Citations (5)
Also Published As
| Publication number | Publication date |
|---|---|
| EP3313419B1 (en) | 2020-08-19 |
| WO2016209816A1 (en) | 2016-12-29 |
| US20170128565A1 (en) | 2017-05-11 |
| EP3756676A1 (en) | 2020-12-30 |
| HK1254397A1 (zh) | 2019-07-19 |
| US11103577B2 (en) | 2021-08-31 |
| US10342864B2 (en) | 2019-07-09 |
| EP3313419A1 (en) | 2018-05-02 |
| US20200016261A1 (en) | 2020-01-16 |
| EP3756676B1 (en) | 2023-01-11 |
| JP2018518527A (ja) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11103577B2 (en) | Methods of treating CMV retinitis by T cell therapy | |
| ES2966045T3 (es) | Vehículos basados en células para la potenciación de la terapia viral | |
| US10537621B2 (en) | Vaccine comprising beta-herpesvirus | |
| Gallichan et al. | Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. | |
| Herz et al. | Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells | |
| Brown et al. | Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection | |
| Schachtele et al. | Glial cells suppress postencephalitic CD8+ T lymphocytes through PD‐L1 | |
| Laursen et al. | Characterizaton of gamma delta T cells in Marek’s disease virus (Gallid herpesvirus 2) infection of chickens | |
| Hao et al. | An anti-tumor vaccine against Marek's disease virus induces differential activation and memory response of γδ T cells and CD8 T cells in chickens | |
| Chentoufi et al. | Combinatorial herpes simplex vaccine strategies: from bedside to bench and back | |
| McElroy et al. | Immune barriers of Ebola virus infection | |
| Melo-Silva et al. | Innate and adaptive immune responses that control lymph-borne viruses in the draining lymph node | |
| Park et al. | Identification of H‐2Kb‐restricted T‐cell epitopes within the nucleocapsid protein of Hantaan virus and establishment of cytotoxic T‐cell clones | |
| Hioe et al. | Induction and activity of class II-restricted, Lyt-2+ cytolytic T lymphocytes specific for the influenza H5 hemagglutinin. | |
| Kanakry et al. | Epstein–Barr Virus Infection | |
| JP2022517322A (ja) | 組み換え単純ヘルペスウイルス２（ｈｓｖ－２）ワクチンベクターを使用する免疫の受動伝達 | |
| Yin et al. | CD137 costimulation is associated with reduced herpetic stromal keratitis and with developing normal CD8+ T cells in trigeminal ganglia | |
| MGM Verjans et al. | Herpes simplex virus-induced ocular diseases: detrimental interaction between virus and host | |
| Mami et al. | Cracking the human cytomegalovirus code: trinary challenges of latency, immune evasion, and correlates of protection | |
| Bergerhausen | The generation and characterization of a beneficial anti-tumoral Lymphocytic choriomeningitis virus strain | |
| Carroll | Contributions of Innate and Adaptive Immunity in the Development of Herpes Stromal Keratitis After Corneal HSV-1 Infection | |
| Cohrs et al. | 2016 Colorado alphaherpesvirus latency society symposium | |
| Miller Jr | Coping with Stress: Rewiring of Host Stress Responses by Human Cytomegalovirus to Redirect Protein Translation | |
| Nichols | An analysis of human cytomegalovirus gene family function | |
| Khaled | Evaluation of Marek’s Disease Virus Induced Immunosuppression Induced by Very Virulent Plus Marek’s Disease Virus in Meat Type Chickens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180417 |
|
| WD01 | Invention patent application deemed withdrawn after publication |